ALT — Altimmune, Inc.

Is ALT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of October 3, 2026

Altimmune, Inc. (ALT) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $2.73. The rating moved from Oversold to Strong Oversold on September 30, 2026.

See all oversold Healthcare stocks →

AI analysis

Altimmune, Inc. (ALT) remains a pipeline-driven small-cap biotech where near-term performance depends on clinical readouts, cash runway and partnership activity. Limited current revenues and exposure to a risk-averse funding environment raise dilution and execution risk, while successful data or licensing deals could produce material upside. Policy headwinds around drug pricing and competitive dynamics in specialty therapeutics add uncertainty to commercial prospects. Investors should monitor upcoming milestones, cash-burn cadence, and any financing or collaboration announcements for directional clarity.

Key factors

  • Pipeline-centric company with value strongly tied to a small number of clinical programs and upcoming readouts or partnership opportunities
  • Limited or negative current revenue; financial flexibility and cash runway will drive near-term dilution risk and strategic options
  • Macroeconomic risk-off environment reducing appetite for early-stage biotech and healthcare IPO/activity, lowering near-term liquidity and secondary funding prospects
  • Sector-level policy pressure (Medicare negotiation / IRA) increases pricing and reimbursement uncertainty for specialty therapeutics
  • Potential upside from positive clinical data or licensing partnerships which could materially re-rate the equity
  • Market perception and trading liquidity are likely to remain volatile given small-cap biotech status and sensitivity to news flow

Risks

  • Clinical trial failure or disappointing data readouts for lead programs, causing sharp share-price declines
  • Need to raise additional capital within a constrained market, leading to dilution or unfavorable financing terms
  • Regulatory or payer hurdles that limit commercial potential or reimbursement for successful assets
  • Competition from larger biopharma companies and novel therapeutic classes that could reduce addressable market share
  • Broader market risk-off sentiment and reduced IPO/secondary market activity that limit exit options and partner interest
  • Operational execution risk (enrollment delays, manufacturing/supply issues) that can push timelines and increase cash burn

See today's live rating, score and targets

Members see the live hourly rating for ALT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.